(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Giulia Marvaso discussing the optimal management of ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Henk van der Poel discussing the optimal management of ...

FDA fast track enables increased FDA-company interactions and potential rolling BLA submission to accelerate development for serious diseases with unmet need. AKY-1189 uses a miniprotein ...

Add Yahoo as a preferred source to see more of our stories on Google. On the list of medical terms we’d rather never hear, cancer is at the top. But when it comes to fighting it, knowledge is ...

Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...

The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...

This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced urothelial cancer who tested positive for ctDNA derived significant benefit from adjuvant ...

Human epidermal growth factor receptor 2 (HER2)–directed antibody–drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally ...

Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...

Complementary advances in molecular imaging and targeted therapeutics for urothelial cancer are providing new opportunities for more effective personalized treatment. Tumor-specific positron emission ...